Despite the success of trastuzumab and pertuzumab, approximately 15–20% of patients with HER2-positive breast cancer do not respond to these therapies initially, and up to 50% may develop resistance after an initial period of clinical benefit. Here, ERBB2 is linked to breast cancer.